For the Inventor, By the Inventor

Enter inventor name

Santa Clara, CA, United States of America

Nathan C Geething

USPTO Granted Patents = 20 (Patent Applications = 15)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 6.9

ph-index = 12

Forward Citations = 334(Granted Patents)

Location History:

San Juan, PR (US) (2016)
Santa Clara, CA (US) (2014 - 2020)
Natick, MA (US) (2018 - 2024)

Company Filing History:

Amunix Operating Inc.

Amunix Pharmaceuticals, Inc

Bioverativ Therapeutics Inc.

Years Active: 2014-2024

Loading Chart...

Loading Chart...

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12071456 - Extended recombinant polypeptides and compositions comprising same (2024-08-27),

2. 10961287 - Extended recombinant polypeptides and compositions comprising same (2021-03-30),

3. 10870874 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2020-12-22),

4. 10421798 - Factor VIII compositions and methods of making and using same (2019-09-24),

5. 10000543 - Glucose-regulating polypeptides and methods of making and using same (2018-06-19),

6. 9976166 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2018-05-22),

7. 9926351 - Extended recombinant polypeptides and compositions comprising same (2018-03-27),

8. 9849188 - Growth hormone polypeptides and methods of making and using same (2017-12-26),

9. 9758776 - Coagulation factor IX compositions and methods of making and using same (2017-09-12),

10. 9540430 - Glucose-regulating polypeptides and methods of making and using same (2017-01-10),

11. 9376672 - Coagulation factor IX compositions and methods of making and using same (2016-06-28),

12. 9371369 - Extended recombinant polypeptides and compositions comprising same (2016-06-21),

13. 9249211 - Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same (2016-02-02),

14. 9168312 - Growth hormone polypeptides and methods of making and using same (2015-10-27),

15. 9062299 - Coagulation factor IX compositions and methods of making and using same (2015-06-23),

Title: Nathan C Geething: Innovator in Biologics and Therapeutics

Introduction: Nathan C Geething is a prominent inventor based in Santa Clara, California, with a remarkable portfolio of 20 patents. His contributions to the field of biotechnology, particularly in the development of biologically active proteins and innovative therapeutic compositions, have positioned him as a key figure in the industry.

Latest Patents: Among his latest inventions, Nathan has developed compositions that incorporate extended recombinant polypeptides (XTEN). These biologically active proteins are designed for the treatment of various conditions, including glucose-related diseases, metabolic disorders, coagulation disorders, and growth hormone-related disorders. His pioneering work offers significant potential for advancing therapeutic options in these critical health areas.

Career Highlights: Nathan has played a crucial role in the biotechnology sector, notably with companies such as Amunix Operating Inc. and Amunix Pharmaceuticals, Inc. His work has not only contributed to the advancement of medical treatments but has also established him as a respected inventor and leader in his field.

Collaborations: Throughout his career, Nathan has collaborated with notable professionals, including Volker Schellenberger and Joshua A. Silverman. These partnerships have facilitated innovation and the successful development of groundbreaking biotechnological products.

Conclusion: Nathan C Geething's contributions to the field of biotechnology through his extensive patent portfolio reflect his commitment to advancing medical science. His innovations in recombinant polypeptides and therapeutic compositions continue to pave the way for new treatment strategies, ultimately benefiting patients and the medical community alike.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…